157 related articles for article (PubMed ID: 34359966)
1. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
[TBL] [Abstract][Full Text] [Related]
2. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
Front Immunol; 2018; 9():1062. PubMed ID: 29899740
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality.
von Auw N; Serfling R; Kitte R; Hilger N; Zhang C; Gebhardt C; Duenkel A; Franz P; Koehl U; Fricke S; Tretbar US
Sci Rep; 2023 Oct; 13(1):18160. PubMed ID: 37875523
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
Capsomidis A; Benthall G; Van Acker HH; Fisher J; Kramer AM; Abeln Z; Majani Y; Gileadi T; Wallace R; Gustafsson K; Flutter B; Anderson J
Mol Ther; 2018 Feb; 26(2):354-365. PubMed ID: 29310916
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
[TBL] [Abstract][Full Text] [Related]
7. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.
Yu T; Jhita N; Shankles P; Fedanov A; Kramer N; Raikar SS; Sulchek T
Lab Chip; 2023 Nov; 23(22):4804-4820. PubMed ID: 37830228
[TBL] [Abstract][Full Text] [Related]
8. A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors.
Hood T; Slingsby F; Sandner V; Geis W; Schmidberger T; Bevan N; Vicard Q; Hengst J; Springuel P; Dianat N; Rafiq QA
Front Immunol; 2024; 15():1335932. PubMed ID: 38655265
[No Abstract] [Full Text] [Related]
9. Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform.
Trainor N; Purpura KA; Middleton K; Fargo K; Hails L; Vicentini-Hogan M; McRobie C; Daniels R; Densham P; Gardin P; Fouks M; Brayer H; Malka RG; Rodin A; Ogen T; Besser MJ; Smith T; Leonard D; Bryan A
Cytotherapy; 2023 Dec; 25(12):1349-1360. PubMed ID: 37690020
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor.
Machietto R; Giacobbe N; Perazzelli J; Hofmann TJ; Barz Leahy A; Grupp SA; Wang Y; Kadauke S
J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607096
[TBL] [Abstract][Full Text] [Related]
11. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.
Nowakowska P; Romanski A; Miller N; Odendahl M; Bonig H; Zhang C; Seifried E; Wels WS; Tonn T
Cancer Immunol Immunother; 2018 Jan; 67(1):25-38. PubMed ID: 28879551
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the importance of culture pH on CD22 CAR T-cells characteristics.
Prochazkova M; Dreyzin A; Shao L; Garces P; Cai Y; Shi R; Pelayo A; Kim YS; Pham V; Frodigh SE; Fenton S; Karangwa C; Su Y; Martin K; Zhang N; Highfill SL; Somerville RP; Shah NN; Stroncek DF; Jin P
J Transl Med; 2024 Apr; 22(1):384. PubMed ID: 38659083
[TBL] [Abstract][Full Text] [Related]
13. Inducing T cell dysfunction by chronic stimulation of CAR-engineered T cells targeting cancer cells in suspension cultures.
Selli ME; Landmann JH; Arveseth C; Singh N
STAR Protoc; 2023 Mar; 4(1):101954. PubMed ID: 36607811
[TBL] [Abstract][Full Text] [Related]
14. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
Netsrithong R; Wattanapanitch M
Front Immunol; 2021; 12():759558. PubMed ID: 34650571
[TBL] [Abstract][Full Text] [Related]
15. Use of polyvinyl alcohol for chimeric antigen receptor T-cell expansion.
Nishimura T; Hsu I; Martinez-Krams DC; Nakauchi Y; Majeti R; Yamazaki S; Nakauchi H; Wilkinson AC
Exp Hematol; 2019 Dec; 80():16-20. PubMed ID: 31874780
[TBL] [Abstract][Full Text] [Related]
16. CD8
Lee SY; Lee DH; Sun W; Cervantes-Contreras F; Basom RS; Wu F; Liu S; Rai R; Mirzaei HR; O'Steen S; Green DJ; Shadman M; Till BG
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38251688
[TBL] [Abstract][Full Text] [Related]
17. Magnetic CAR T cell purification using an anti-G4S linker antibody.
Harrer DC; Li SS; Kaljanac M; Bezler V; Barden M; Pan H; Herr W; Abken H
J Immunol Methods; 2024 May; 528():113667. PubMed ID: 38574803
[TBL] [Abstract][Full Text] [Related]
18. The role of cryopreservation techniques in manufacturing, transport, and storage of Car-T therapy products.
Jandova M; Stacey GN; Lanska M; Gregor I; Rozsivalova P; Bekova L; Duchacova ZW; Belada D; Radocha J; Mericka P; Fuller B
Cryo Letters; 2023; 44(3):123-133. PubMed ID: 37883165
[TBL] [Abstract][Full Text] [Related]
19. Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation.
Lee NK; Chang JW
Ann Lab Med; 2024 Jul; 44(4):314-323. PubMed ID: 38361427
[TBL] [Abstract][Full Text] [Related]
20. Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function.
Repellin CE; Ganesan P; Alcudia JF; Lakshmireddy HKD; Patel P; Beviglia L; Javitz HS; Sambucetti L; Bhatnagar P
Adv Biosyst; 2020 Jan; 4(1):e1900224. PubMed ID: 32293122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
